As of Oct 27
| +0.0101 / +0.25%|
The 3 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 8.00, with a high estimate of 20.00 and a low estimate of 6.50. The median estimate represents a +94.17% increase from the last price of 4.12.
The current consensus among 4 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.